Ironically, a drug meant to help you breathe easier.
Contact Us Now

For a free, confidential

Ketek Liver Failure Drug Injury Lawsuit

Research shows the antibiotic telithromycin—sold under the brand name Ketek—causes autoimmune neuromuscular disease myasthenia gravis and acute liver failure. The Rottenstein Law Group compassionately advocates for those who have suffered from the harmful side effects of potentially dangerous drugs.

If you’ve taken Ketek and believe it harmed you, contact RLG for a free, confidential legal consultation immediately. We will evaluate your case and remain on the lookout for Ketek recalls and Ketek class action lawsuits. We might be the Ketek law firm you are looking for.

What Is Ketek, and What Is It Prescribed For?

Ketek is a brand name for the drug telithromycin. Made and sold by the French pharmaceutical company Sanofi-Aventis, this prescription medication is used to treat mild to moderate respiratory infections such as bronchitis, sinusitis, and pneumonia.

In 1998, Hoeschst Marion Roussel, one of Sanofi-Aventis’ predecessors, ran clinical trials of telithromycin. The European Commission approved the drug in 2001, and the FDA approved Ketek in April 2004. Sanofi-Aventis began selling Ketek in tablet forms in 300mg and 400mg doses taken twice daily with or without food. In 2005, Ketek sales reached $264 million, 70 percent of which occurred in the United States. By 2007, doctors had written 6 million prescriptions for the drug.

Telithromycin is a ketolide antibiotic that disrupts protein synthesis inside bacteria cells. After ingestion, the liver metabolizes it. Unfortunately, the drug causes side effects that are largely gastrointestinal in nature, including diarrhea, nausea, abdominal pain, and vomiting.

Since 2006 controversies have eroded consumer confidence in Ketek. Consequently, in February 2007, the FDA placed a “black box warning,” the agency’s most serious alert, on Ketek. There are no known efforts to issue a Ketek recall or ban the drug, but dozens of harmed Ketek users have filed lawsuits against Sanofi-Aventis.

Ketek Might Cause Life-Threatening Side Effects

On February 12, 2007, the U.S. Food and Drug Administration (FDA) reduced the number diseases Ketek could be prescribed for from 3 to 1. Doctors could no longer prescribe the antibiotic for acute bacterial sinusitis and chronic bronchitis because the benefits the drugs provided paled to the risks the drug caused, especially to users’ livers. The FDA also required Sanofi-Aventis to provide a “black box” warning on Ketek to ensure that those with an autoimmune neuromuscular disease, myasthenia gravis, would not take the drug. Ketek can still be prescribed for mild to moderate forms of pneumonia, but in November 2007, plaintiffs filed a Ketek class action lawsuit against Sanofi-Aventis in Illinois. Read more

RLG’s Lawyers Will Make Things Easier

The process of demanding compensation for the harm you’ve suffered can be complicated, even if it doesn’t seem fair that you should have to go through even more trouble to be made whole again. The lawyers at the Rottenstein Law Group believe that obtaining legal satisfaction from those who harmed you shouldn’t require more hardship. That’s why we do everything we can to streamline the process, and we will file a Ketek lawsuit on your behalf if necessary. RLG will also keep you up to date on any Ketek class action lawsuits, FDA Ketek warnings, and Ketek FDA recall announcements.

If you have taken Ketek and believe it harmed you, contact RLG today.

Join the Discussion

Please note: Comments are encouraged in order to permit visitors to discuss relevant topics. Comments are moderated and might be edited by RLG before being published.

Comments should not be used to ask questions of RLG’s lawyers; if you want to speak with a lawyer, please fill out this contact form or call 1 (888) 976-8529. *Your name and email address will not be published.



three + = 11

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

RLG encourages you to reproduce our original content—on your own web site; in emails to your friends and family; in blogs, posts, and tweets, etc.—but we ask that you please attribute whatever you use to us, and, whenever possible, provide a link to the page where you first found the material. That way, whoever reads your excerpt might read more informative material of interest at one of RLG's sites.
You’ve taken enough. We'll take it from here. Click here to contact us now.